Citations

Clear

3501 citation(s) found for "Xu, Timothy".

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin, D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Sborov, Douglas W. , Valent, Jason , Varshavsky‐Yanovsky, Asya, Snedeker, Jenna, Holmberg, Leona , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Castillo, Jorge J. , Costello, Caitlin , Devarakonda, Srinivas , Garfall, Alfred L. , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 19, 2024 | Volume: 22 | Issue: 1D | Pages: 1-19

10.6004/jnccn.2024.0001 | PMID 38244272 Get It

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
Patient characteristics associated with acute kidney injury following coronary angiography
Knott, Jonathan D , Engheta, Michael , Michel, Jeffery, Mixon, Timothy A. , Widmer, R. Jay , Knott, Jonathan , Widmer, Robert Jay

Mayo Clinic

Baylor University Medical Center Proceedings | January 17, 2024 | Volume: 37 | Issue: 3 | Pages: 382-387

10.1080/08998280.2024.2301903 | PMID 38628321 Get It

Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir, Chowdhury Arif , Page, David B. , Broeckx, Glenn , Gonzalez, Claudia Aura, Burke, Caoimbhe, Murphy, Clodagh, Reis‐Filho, Jorge S. , Gupta, Rajarsi , Vieth, Michael, Hida, Akira I. , Kahila, Mohamed M. , Kos, Zuzana , Verbandt, Sara , Thagaard, Jeppe , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hewitt, Stephen M. , Husain, Zaheed, Irshad, Sheeba , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Scott, Ely, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Durga, Kharidehal, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Hytopoulos, Evangelos, Mahon, Sarah, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Verghese, Gregory , Viale, Giuseppe , Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Stovgaard, Elisabeth Specht , Salgado, Roberto , Gupta, Rajarsi R , Chardas, Alexandros , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Lennerz, Jochen , Loi, Sherene , Reis-Filho, Jorge S , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , Ly, Amy , Harms, Paul W. , Diest, P. J. van , AbdulJabbar, Khalid , Adams, Sylvia , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Janssen, Emiel A. M. , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Aktürk, Güray , Kovács, Anikó , Lerousseau, Marvin , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rajpoot, Nasir , Rapoport, Bernardo L. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sughayer, Maher A. , Sur, Daniel Genel , Symmans, W. Fraser , Teuwen, Jonas , Tran, William T, Laak, Jeroen van der , Yuan, Yinyin , Denkert, Carsten , Savas, Peter Stephen , Gallagher, William M. , Rahman, Arman

Mayo Clinic

The Journal of Pathology | January 17, 2024 | Volume: 262 | Issue: 3 | Pages: 271-288

10.1002/path.6238 | PMID 38230434 Get It

Abstract Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Importance of Diversity, Equity, and Inclusion in the Hepatopancreatobiliary Workforce
Rengers, Timothy A. , Warner, Susanne G.

Mayo Clinic

Cancers | January 11, 2024 | Volume: 16 | Issue: 2 | Pages: 326

10.3390/cancers16020326 | PMID 38254815 Get It

Diversity is a catalyst for progress that prevents institutional stagnation and, by extension, averts descent to mediocrity. This review focuses on the available data concerning hepatopancreatobiliary (HPB) surgical workforce demographics and identifies evidence-based strategies that may enhance justice, equity, diversity, and inclusion for HPB surgeons and their patients. We report that the current United States HPB surgical workforce does not reflect the population it serves. We review data describing disparity-perpetuating hurdles confronting physicians from minority groups underrepresented in medicine at each stage of training. We further examine evidence showing widespread racial and socioeconomic disparities in HPB surgical care and review the effects of workforce diversity and physician–patient demographic concordance on healthcare outcomes. Evidence-based mitigators of structural racism and segregation are reviewed, including tailored interventions that can address social determinants of health toward the achievement of true excellence in HPB surgical care. Lastly, select evidence-based data driving surgical workforce solutions are reviewed, including intentional compensation plans, mentorship, and sponsorship.
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma
Kahl, Brad S. , Jegede, Opeyemi A. , Peterson, Christopher G., Swinnen, Lode J., Weiss, Matthias , Fishkin, Paul A. S., Fenske, Timothy S. , Williams, Michael E. , Weiss, Matthias , Fenske, Timothy S , Williams, Michael E , Jagede, Opeyemi A. , Kahl, Brad S , Peterson, Christopher, Habermann, Thomas M. , Schuster, Stephen J.

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 7 | Pages: 774-778

10.1200/jco.23.01912 | PMID 38194625 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In 2003, the Eastern Cooperative Oncology Group initiated a randomized phase III clinical trial (E4402) comparing two different rituximab dosing strategies for patients with previously untreated low–tumor burden follicular lymphoma. Rituximab-responsive patients (n = 299) were randomly assigned to either a retreatment rituximab (RR) strategy or a maintenance rituximab (MR) strategy. Each dosing strategy was continued until treatment failure. The primary end point of the study was time to treatment failure (TTF). In the original report, there was no difference in TTF between the two dosing strategies. Here, we report on the long-term outcomes for secondary end points of time to first cytotoxic therapy, duration of response, and overall survival (OS). At 7 years, 83% of MR patients had not required first chemotherapy compared with 63% of RR patients (hazard ratio, 2.37 [95% CI, 1.5 to 3.76]). At 7 years, 71% of MR remained in their first remission compared with 37% of RR patients. Despite the improved first remission length with MR, there was no difference in OS at 10 years (83% v 84%). With mature long-term data, we confirm that prolonged maintenance rituximab does not confer an OS advantage in low–tumor burden follicular lymphoma.
A review of epidural and non-epidural contrast flow patterns during fluoroscopic and CT-guided epidural steroid injections
Madhavan, Ajay A. , Maus, Timothy P. , Murthy, Naveen S. , Rhodes, Nicholas G. , Tiegs‐Heiden, Christin A. , Baffour, Francis , Diehn, Felix E. , Rhodes, Nicholas G , Tiegs-Heiden, Christin A , Madhavan, Ajay A , Liebo, Greta B.

Mayo Clinic

Interventional Neuroradiology | January 5, 2024 | Volume: 32 | Issue: 4 | Pages: 1935-1947

10.1177/15910199231221857 | PMID 38179603 Get It

Epidural steroid injections are commonly performed using fluoroscopic or CT guidance. With both modalities, the injection of contrast material is necessary before steroid administration to ensure adequate epidural flow and exclude non-epidural flow. While fluoroscopic guidance is conventional, CT is utilized at some centers and can be particularly helpful in the setting of challenging or postoperative anatomy. It is important for proceduralists to be adept at evaluating contrast media flow patterns under both modalities. The goal of this review article is to describe and provide examples of epidural and non-epidural flow patterns on both conventional fluoroscopy and CT. Specific non-epidural patterns discussed include intrathecal flow, intradural/subdural flow, vascular uptake, flow into the retrodural space of Okada, inadvertent facet joint flow, and intradiscal flow.
Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.

Mayo Clinic

Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available

10.1128/jvi.01791-23 | PMID 38168672 Get It

ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline
Gebre, Robel K , Raghavan, Sheelakumari, Hofrenning, Ekaterina I. , Przybelski, Scott A. , Lesnick, Timothy G. , Vassilaki, Maria , Petersen, Ronald C. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Raghavan, Sheelakumari , Knopman, David S. , Machulda, Mary M. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082831 Get It

AbstractBackgroundThe mapping between risk factors and biomarkers with cognitive performance and decline in the older adults is complex and varies significantly across different age and sex groups. Our goals were to (i) develop a machine learning (ML) model to predict baseline cognition and cognitive decline over a 5‐year follow‐up using only baseline assessments, and (ii) identify important modifiable and non‐modifiable predictors of cognitive decline across different age strata.MethodWe utilized longitudinal data from 2219 participants (mean age (SD): 70 (12) years, 49% male) from Mayo Clinic Study of Aging who had 43 features belonging to cardiovascular health, plasma, MRI (diffusion and structural), and lifestyle measures. Cognition was measured using a global cognition z‐score. We built ML models to predict baseline cognition and rate of cognitive decline over 5‐years (linear regression slopes over all individual followup measurements for each participant) using baseline assessments as inputs. We then built a model for each category separately and as a pooled model with all measures included, incorporating education and sex as demographic features in all models (Fig. 1). We applied a multi‐layer stack ensemble ML technique that utilized repeated k‐fold bagging to maximize accuracy. Importance of the top predictors were assessed in three age strata (55‐65 years (31%), 65‐80 years (46%), 80‐95 years (23%)).ResultThe pooled model explained the largest variance for prediction of baseline cognition and cognitive decline (Fig. 2). In individuals ≤80 years, lower NfL was most predictive of higher baseline cognition. A combination of imaging and plasma features predicted the 5‐year cognitive decline. Additionally, in individuals ≤65 years, diabetes and hypertension were important predictors of faster cognitive decline and in those >80, lower BMI and midlife physical/cognitive activity was an important predictor of faster cognitive decline (Fig. 3).ConclusionThe plasma model was best for baseline cognition prediction and imaging model was best for cognitive decline prediction. There was significant heterogeneity in important features across the age strata. In individuals >65 years, plasma GFAP was the most important predictor of cognitive decline. Our model allowed identification of key risk factors that predicted cognitive decline.
Visual versus quantitative assessments using Pittsburgh compound‐B and Flutemetamol PET scans across age groups
Lee, Jeyeon , Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Kemp, Bradley J. , Lowe, Val J. , Zeydan, Burcu , Johnson, Derek R. , Schwarz, Christopher G. , Senjem, Matthew L. , Min, Hoon-Ki Paul , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082897 Get It

AbstractBackgroundBoth 11C‐Pittsburgh compound‐B (PiB) and 18F‐Flutemetamol (FMT) have off‐target white matter (WM) signal that increases with age, but WM uptake is stronger with FMT than PiB. Although their WM patterns are comparably associated with age, the difference between them may impact visual and quantitative assessments of cortical amyloid‐β uptake. Our objective was to determine whether PiB PET and FMT PET visual assessments agree with quantitative cortical amyloid‐β evaluations.MethodA cohort of cognitively unimpaired (CU) younger adults with median (range) of 39 (30, 48) years (N = 30), CU older adults with age of 67 (61, 83) years (N = 30) and older adults with AD dementia with age of 67 (54‐84) years (N = 23) underwent MRI, PiB PET and FMT PET. PiB‐PET and FMT PET scans were evaluated visually by two nuclear medicine specialists blinded to participant information. Disagreements were reconciled with a second, joint round of visual reads. Readers applied standard visual assessment criteria using the absence of regional gray matter (GM) and WM contrast as an indication of a positive scan. The global cortical PiB standard uptake value ratio (SUVr) was obtained referencing to cerebellar crus uptake and converted to centiloid values. Participants were classified as PiB positive/negative using a centiloid cut‐off of 22.ResultPiB and FMT visual positivity agreed with quantitative positivity on PiB‐based centiloid values in 69/83 for PiB and 78/83 for FMT. There were 10 disagreements with PiB, 1 disagreement with FMT and 4 disagreements with both. Few disagreements occurred near the centiloid threshold. Interestingly, all disagreements between visual reads (amyloid‐β positive) and centiloid (amyloid‐β negative) in the CU younger were with PiB. FMT disagreements were always in the CU older and AD groups.ConclusionDisagreements between amyloid‐β positivity on visual reads and quantitative measurements (centiloid) may depend on age and tracer. PiB WM uptake is lower than FMT WM uptake, which may lead to reduced contrast between GM and WM (part of the standard criteria for visual reads), especially in younger ages. In contrast, WM uptake increases at older ages, and increased WM signal may bleed more into cortical regions, hiding subtle, near‐threshold cortical uptake, especially with FMT.